Nanoparticle-mediated metabolic reprogramming for immune modulation in inflammatory diseases.

Area of Science:

• Immunometabolism
• Nanomedicine
• Inflammatory Diseases

Background:

• Immune cell metabolic dysregulation, including abnormal glycolysis and mitochondrial dysfunction, drives inflammatory diseases.
• Metabolic reprogramming is crucial in chronic inflammation, but current strategies lack specificity, causing off-target effects.
• Nanoparticle-based therapies offer a precise platform for modulating immune cell metabolism, enhancing bioavailability and reducing toxicity.

Purpose of the Study:

• To systematically review nanoparticle-mediated metabolic reprogramming for treating inflammatory diseases.
• To explore how engineered nanocarriers can precisely target and modulate immune cell metabolism.
• To analyze the clinical efficacy and safety of nanoparticle-based immunometabolic therapies.

Main Methods:

• Systematic review of literature on nanoparticle-based immunometabolic regulation.
• Analysis of nanocarrier properties and their role in immune modulation.
• Examination of early-stage clinical studies and patent landscape for nanoparticle therapies.

Main Results:

• Nanoparticles act as effective delivery vehicles for metabolic modulators.
• Nanoparticles actively participate in immune regulation via their physicochemical properties.
• Early clinical data and patents show promising efficacy and safety for nanoparticle-based metabolic therapies.

Conclusions:

• Nanoparticle-mediated immunometabolic reprogramming is a transformative approach for precision intervention in inflammatory diseases.
• Engineered nanocarriers offer enhanced specificity and reduced toxicity compared to conventional therapies.
• This strategy holds significant potential for developing novel treatments for a range of inflammatory conditions.